• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    3/20/24 5:34:27 PM ET
    $APDN
    $AVGR
    $BPTS
    $ETAO
    Other Consumer Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $APDN alert in real time by email

    Gainers

    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million.
    • Leap Therapeutics (NASDAQ:LPTX) shares rose 11.21% to $2.84. The market value of their outstanding shares is at $72.6 million. As per the press release, Q4 earnings came out 2 days ago.
    • Jaguar Health (NASDAQ:JAGX) stock rose 10.94% to $0.09. The company's market cap stands at $18.2 million.
    • Sharps Technology (NASDAQ:STSS) shares moved upwards by 9.73% to $0.37. The market value of their outstanding shares is at $5.6 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares rose 8.88% to $1.96. The company's market cap stands at $7.1 million.
    • Iterum Therapeutics (NASDAQ:ITRM) shares rose 7.59% to $1.7. The company's market cap stands at $22.8 million.

    Losers

    • Biophytis (NASDAQ:BPTS) shares decreased by 20.8% to $0.36 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million.
    • Fresh2 Group (NASDAQ:FRES) shares declined by 16.63% to $0.62. The market value of their outstanding shares is at $14.6 million.
    • Etao International Co (NASDAQ:ETAO) shares decreased by 14.01% to $0.23. The market value of their outstanding shares is at $23.7 million.
    • Avinger (NASDAQ:AVGR) shares declined by 12.13% to $2.9. The company's market cap stands at $3.9 million. As per the news, the Q4 earnings report came out today.
    • Applied DNA Sciences (NASDAQ:APDN) shares decreased by 5.81% to $0.47. The company's market cap stands at $7.9 million.
    • Nexalin Technology (NASDAQ:NXL) stock decreased by 5.38% to $0.44. The market value of their outstanding shares is at $3.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $AVGR
    $BPTS
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025Buy → Neutral
    H.C. Wainwright
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    Leap Therapeutics Inc.
    $LPTX
    6/28/2024$8.00Buy
    Rodman & Renshaw
    Applied DNA Sciences Inc.
    $APDN
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    Avinger Inc.
    $AVGR
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    Biophytis SA
    $BPTS
    10/25/2021$15.00Buy
    HC Wainwright & Co.
    Leap Therapeutics Inc.
    $LPTX
    10/4/2021$6.00Buy
    Mizuho
    Leap Therapeutics Inc.
    $LPTX
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iterum Therapeutics Announces Filing of Winding Up Petition

    DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up the Company. An Order was made appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited (the "Joint Provisional Liquidators"), as Joint Provisional Liquidators to the Company. The petition is due to be heard on April 13, 2026. If a winding up

    3/27/26 9:25:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTL Biopharmaceuticals Announces ADS Ratio Change

    RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-four revers

    3/20/26 4:10:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $APDN
    $AVGR
    $BPTS
    $ETAO
    SEC Filings

    View All

    SEC Form NT 10-K filed by Jaguar Health Inc.

    NT 10-K - Jaguar Health, Inc. (0001585608) (Filer)

    4/1/26 4:19:05 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sharps Technology Inc.

    10-K - Sharps Technology Inc. (0001737995) (Filer)

    3/31/26 4:46:44 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Iterum Therapeutics plc (0001659323) (Filer)

    3/31/26 7:00:07 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Segal Niv

    3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)

    3/23/26 4:01:12 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hillel Fain Osnat

    3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)

    3/23/26 4:01:14 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leap Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

    1/29/25 7:15:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

    1/29/25 7:15:19 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

    6/28/24 8:18:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form SC 13G filed by Iterum Therapeutics plc

    SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 3:31:48 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

    Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t

    11/12/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $AVGR
    $BPTS
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the

    11/12/25 8:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

    DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Ac

    11/7/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care